SSTR2

Somatostatin receptor type 2 · P30874 · SSTR2 on Sugi Atlas →

49,235 patent compounds predicted against SSTR2, 25,153 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ilatreotide (SCHEMBL2111506)	0.91	18/20
Somatostatin Receptor Ligand (SCHEMBL670990)	0.60	17/20
Lanreotide (SCHEMBL1649219)	0.98	16/20
Vapreotide (SCHEMBL4826)	0.81	16/20
Vapreotide (SCHEMBL4827)	0.81	16/20
Vapreotide (SCHEMBL294911)	0.80	16/20
Depreotide (SCHEMBL456503)	0.79	16/20
Octreotide (SCHEMBL2330976)	0.54	16/20
Edotreotide (SCHEMBL1649285)	1.00	15/20
SCHEMBL1239661	0.69	15/20
Octreotide (SCHEMBL247589)	0.57	15/20
SCHEMBL180440	0.80	14/20
SCHEMBL1651014	0.80	14/20
Octreotide (SCHEMBL320745)	0.76	14/20
SCHEMBL835379	0.55	14/20
SCHEMBL836373	0.55	14/20
Mertansine (SCHEMBL762822)	0.55	14/20
SCHEMBL1105134	0.55	14/20
SCHEMBL763400	0.54	14/20
SCHEMBL1105132	0.54	14/20

Clinical trials — most relevant to SSTR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer	PHASE3	RECRUITING
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	PHASE1/PHASE2	RECRUITING
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide	PHASE1/PHASE2	RECRUITING
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake	PHASE2	RECRUITING
Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer	PHASE2	COMPLETED
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors	PHASE1/PHASE2	RECRUITING
Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer	PHASE2	COMPLETED
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours	PHASE2	RECRUITING
Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors	PHASE1/PHASE2	COMPLETED
Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases	PHASE2	NOT_YET_RECRUITING
TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets	PHASE2	COMPLETED
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer	PHASE2	COMPLETED
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors	PHASE1/PHASE2	COMPLETED
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor	PHASE2	RECRUITING
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)	PHASE1/PHASE2	RECRUITING
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression	PHASE2	COMPLETED
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors	PHASE1/PHASE2	RECRUITING
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression	PHASE2	UNKNOWN
Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors	PHASE2	ACTIVE_NOT_RECRUITING
Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC	PHASE1	COMPLETED
Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms	EARLY_PHASE1	COMPLETED
Observational Study on GEP-and Pulm-NET Treated at FPG	nan	RECRUITING
Molecular and Whole-body MR Imaging in Lymphomas	nan	COMPLETED
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly	nan	COMPLETED
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia	nan	NO_LONGER_AVAILABLE
The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging	nan	COMPLETED
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)	nan	NOT_YET_RECRUITING
Epidemiology of Acromegaly in Denmark 1991-2010	nan	UNKNOWN
64Cu-DOTATATE-PET for Lyme Neuroborreliosis	nan	RECRUITING
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SSTR2 binder may also engage these)

Protein	Name	Similarity
P30680	—	1.000	P30680 →
Q49LX6	—	1.000	Q49LX6 →
P34993	—	1.000	P34993 →
P34994	—	1.000	P34994 →
P30875	—	0.999	P30875 →
P34975	—	0.972	P34975 →
P33534	—	0.971	P33534 →
Q95247	—	0.971	Q95247 →
P42866	—	0.966	P42866 →
OPRM1	Mu-type opioid receptor	0.966	landscape →
P79350	—	0.966	P79350 →
Q49LX5	—	0.965	Q49LX5 →
SSTR1	Somatostatin receptor type 1	0.965	landscape →
O42179	—	0.964	O42179 →
Q5IS39	—	0.964	Q5IS39 →
P33535	—	0.964	P33535 →
Q95M54	—	0.964	Q95M54 →
Q5IS84	—	0.963	Q5IS84 →
P30873	—	0.962	P30873 →
Q9MYW9	—	0.962	Q9MYW9 →
P28646	—	0.961	P28646 →
OPRK1	Kappa-type opioid receptor	0.957	landscape →
P41144	—	0.951	P41144 →
Q2KIP6	—	0.951	Q2KIP6 →
Q9DDN6	—	0.947	Q9DDN6 →
P70031	—	0.947	P70031 →
CCKAR	Cholecystokinin receptor type A	0.946	landscape →
O62809	—	0.946	O62809 →
O02836	—	0.944	O02836 →
P47751	—	0.944	P47751 →